Table 1.
Patient demographics and clinical characteristics of patients at baseline (n=89)
| Characteristic | N (%) |
| Median age at diagnosis, years (range) | 53 (16–83) |
| Male | 47 (53) |
| Race | |
| Caucasian | 70 (79) |
| Othert | 4 (4) |
| Unknown | 15 (17) |
| Eye | |
| Left | 38 (43) |
| Right | 37 (42) |
| Unknown | 14 (16) |
| Stage at diagnosis | |
| Limited | 83 (93) |
| Metastatic | 5 (6) |
| Unknown | 1 (1) |
| Molecular risk | |
| High | 28 (31) |
| Low | 3 (3) |
| Unknown | 58 (65) |
| Time to metastasis, mo (range) | 37.8 (3.7–212.7) |
| Median no of prior therapies, no (range) | 0 (0–4) |
| Received prior therapy | |
| Any prior therapy | 40 (45) |
| Liver directed therapy | 26 (29) |
| Systemic therapy | 25 (28) |
| Radiation | 13 (15) |
| Immunotherapy | 20 (22) |
| Targeted therapy | 12 (13) |
| Chemotherapy | 2 (2) |
| Performance status at treatment start | |
| 0 | 50 (56) |
| 1 | 21 (24) |
| 2 | 4 (4) |
| Unknown | 14 (16) |
| LDH at treatment start | |
| Normal | 23 (26) |
| High | 16 (18) |
| Unknown | 50 (56) |